Unmasking Neurotrophic Keratitis: Diagnosing and Treating All Stages (CME/CE Symposium)

Activity Description and Purpose

Neurotrophic keratitis (NK) is a degenerative corneal condition due to decreased or absent sensory corneal innervation. Early diagnosis can be challenging. Optimal treatment of all stages of NK is crucial for restoring epithelial integrity, mitigating progression of corneal damage, and preventing recurrent defects. This case-based educational activity can help “unmask” potential best practices in the diagnosis and treatment of all stages of NK.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Integrate evaluation of corneal sensitivity into routine assessment of ocular surface disease
  • Select treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 COPE
  • 1.50 Participation
Course opens: 
04/24/2023
Course expires: 
04/24/2023

Faculty

Lisa M. Nijm, MD, JD (Chair)
Assistant Professor of Ophthalmology
University of Illinois Eye and Ear Infirmary
Chicago, Illinois
Founder and Medical Director
Warrenville EyeCare and LASIK Center
Warrenville, Illinois

W. Barry Lee, MD, FACS
Co-Medical Director
Georgia Eye Bank
Partner
Eye Consultants of Atlanta
Atlanta, Georgia

Leslie E. O’Dell, OD, FAAO
Medical Director and Director of Clinical Research
Medical Optometry America
Shrewsbury, Pennsylvania

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

W. Barry Lee, MD, has no relevant commercial relationships to disclose.

Lisa M. Nijm, MD, JD, is a consultant for Alcon, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TruKera Medical, Thea Pharmaceuticals Limited, and Visus Therapeutics; is an advisory board member of Alcon, Allergan, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, and Trukera Medical; is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has stock options in TruKera Medical that have not been exercised.

Leslie E. O’Dell, OD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Eye Eco Inc, Eyedetec Medical, Inc, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Allergan, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in Èssiri Labs and Eyedetec Medical, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 84174-TD
COPE Course Category: Treatment & Management of Ocular Disease
Administrator:

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Dompé US, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.

©2023 MedEdicus LLC. 298.1

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 COPE
  • 1.50 Participation
Please login or register to take this course.

Click Take course to proceed to the evaluation and to obtain your certificate.